T-cell receptors (TCRs) are membrane anchored heterodimers structurally related to antibody molecules. Single-chain antibodies can be engineered by linking the two variable domains, which fold properly by themselves. However, proper assembly of the variable domains of a human TCR (Va and Vp) that recognize the HLA-DR2b/myelin basic protein-(85-99) peptide complex was critically dependent on the addition of a third domain, the constant region of the TCR 13 chain (Cp), to the single-chain construct. Single-chain molecules with the three-domain design, but not those with the two-domain design, expressed in a eukaryotic cell as chimeric molecules linked either to glycosyl phosphatidylinositol or to the transmembrane/cytoplasmic domains of the CD3 ' chain were recognized by a conformation-sensitive monoclonal antibody. The chimeric three-domain single-chain TCR linked to CD3 C chain signaled in response to both the specific HLA-DR/peptide and the HLA-DR/superantigen staphylococcal enterotoxin B complexes. Thus, by using this three-domain design, functional single-chain TCR molecules were expressed with high efficiency. The lipid-linked single-chain TCR was solubilized by enzymatic cleavage and purified by affinity chromatography. The apparent requirement of the constant domain for cooperative folding of the two TCR variable domains may reflect significant structural differences between TCR and antibody molecules.
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T-ceil receptor (TCR) recognition of antigen fragments presented by major histocompatibility complex (MHC) molecules is a critical step in the initiation of a specific immune response (1, 2) . The TCR a and p chains are each composed of two immunoglobulin-like domains; most of the amino acid residues that are found to be highly conserved in the variable (V) region of immunoglobulins are also found in TCR V regions, suggesting that the tertiary structure of the TCR may resemble that of immunoglobulins (3, 4) . However, TCR V regions have significantly more primary sequence variability, an increased apparent rate of divergence in phylogeny, and peaks of variability in addition to those noted in immunoglobulins (5, 6) . In order to understand and control the molecular interactions underlying T-cell recognition of MHC/peptide complexes, complete structural knowledge of the TCR is required.
Several approaches have been employed to produce soluble, recombinant TCRs. In these recombinant TCR molecules, the transmembrane/cytoplasmic regions of a and p chains were replaced with sequences from lipid-linked proteins (7), the CD3 ; chain (8) , or immunoglobulins (9, 10) . Soluble TCRs were either recovered as secreted proteins or obtained by enzymatic cleavage of the surface-expressed recombinant proteins. All of these approaches rely, however, on the assembly of the heterodimer, which is inefficient (11) . In addition, high-level expression of the human TCR a chain in transfected eukaryotic cells is not stable. These problems can be avoided by the design of a single-chain (sc) recombinant protein in which the V regions of the heterodimer are joined by a short peptide linker. Such a design has been successfully applied to antibody molecules (12) . Such recombinant molecules, scFv, have a specificity and affinity similar to that of native antibodies (12) . Several reports have described the production of scTCRs in bacterial expression systems using the sc antibody (Fv) design (13) (14) (15) (16) , but none have presented functional data indicating that these scTCRs could recognize their MHC/peptide complexes or superantigens. Recently, however, the production in bacteria of a scTCR with the two-domain Fv design that could recognize its natural ligands has been reported, although the fraction correctly refolded was extremely low (17) .
In the present report, different scTCR designs were evaluated in transfected eukaryotic cells with respect to surface expression of TCR molecules, proper folding, and recognition of the appropriate MHC/peptide ligand. A three-domain sc construct [a-chain V (Va)-linker-P-chain V (Vq)-P-chain constant (Cp)] was stably expressed on the cell surface when linked to a glycosyl phosphatidylinositol (GPI) anchor and recognized by a conformation-dependent monoclonal antibody (mAb) specific for the V,17 segment. The soluble form of this recombinant protein could be readily obtained by enzymatic cleavage with phosphatidylinositol-specific phospholipase C (PI-PLC). Replacement of the GPI domain with the cytoplasmic portion of the chain resulted in a functional TCR molecule that transduced an intracellular signal following recognition of either the proper MHC/peptide or the MHC/staphylococcal enterotoxin B (SEB) superantigen complex. The production of a functional scTCR directly demonstrates the feasibility of employing sc design to produce soluble TCRs.
MATERIALS AND METHODS
Construction of Recombinant TCR Molecules. cDNAs of TCR a and , chains were prepared from mRNA of Hy.2H9 cells (18) with Superscript reverse transcriptase (BRL) and an oligo(dT) primer (Sigma) and were amplified by PCR using Vent DNA polymerase (New England Biolabs) and primers 5'-GCTCGAGGCGGCGATGGAAACTCTCCTGGGAGT-3' (A5) and 5'-GGAATTCAGCTGGACCACAGCCGC-3' for a-chain and 5'-GCTCGAGCTCTGCCATGGACTCCTG-GA-3' and 5'-GGAATTCAGAAATCCTTTCTCTTGAC-3' for 3-chain. The cDNAs were cloned into the mammalian expression vector pBJ-neo (8 Klausner (National Institutes of Health). Convenient restriction sites were engineered at the end of each fragment to aid in the assembly of the construct. The linker was a 15-amino acid motif of GGGGS repeated three times (12) with Sac I at the 5' end and EcoRV at the 3' end. Except for a-PI, all the constructs were cloned into pBJ-neo, which carries the G418-resistance gene. a-PI was cloned into pCEP-4 (Invitrogen), which bears the hygromycin-resistance gene. All constructs were verified by multiple restriction digests and by sequencing with the Sequenase kit (United States Biochemical).
Affinity Purification and Characterization of a Soluble
Three-Domain scTCR. After transfection and G418 selection (8), cells expressing a high level of GPI-linked three-domain scTCR (ABC-PI) were isolated by three rounds of sorting. The resulting cells were grown in spinner culture to a density of 106 per ml and harvested by centrifugation. The pellet was washed twice with phosphate-buffered saline (PBS) and resuspended in PBS containing 2 mM Pefabloc (Centerchem, Stamford, CT) to a density of 5 x 107 per ml with PI-PLC (Sigma) added at 1 unit/ml. Cells were incubated at 37°C for 1 hr with constant rocking. The supernatant was collected by centrifugation and by passage through a 0.45-gm filter and applied to a column of Acti-gel (Sterogen, Arcadia, CA) with immobilized pF1. The column was washed with 10 volumes of PBS and the soluble TCR was eluted with 0.15 M glycine (pH 2.8). Fractions were immediately neutralized with 0.1 volume of saturated Tris. The soluble TCR was then dialyzed against >100 volumes of PBS at 4°C with at least four changes and concentrated to 0.5 mg/ml by vacuum dialysis against PBS. Five micrograms of purified soluble three-domain scTCR was analyzed by SDS/PAGE under reducing conditions.
Stimulation of Transfectants with Antibodies, SEB, and Peptide/MHC Ligands. ABC-;-transfected BW5147P a-/3-(19) cells (5 x 104 per well) were cultured in a 96-well round-bottom plate to which various antibodies had been immobilized (1 Mg per well). The supernatants were collected after 24 hr and interleukin 2 (IL-2) production was assessed in a bioassay using an IL-2-dependent cell line (CTLL) and the CellTiter-96 nonradioactive proliferation assay (Promega). In the case of ABC-v-transfected RBL-2H3 (8) cells, the cells were incubated with [3H]serotonin (NEN) at 0.5 uCi (18.5 kBq) for 24 hr before they were added to the antibody plate. After incubation at 37°C for 2 hr, radioactivity released into the supernatant was measured in a liquid scintillation counter. The specific serotonin release was calculated as described (8 High-level expression of the TCR a chain (a-PI) was, however, not stable either alone or in the presence of (-PI. Attempts were made on several cell lines, including COS-7, CHO-Kl, and a TCR-deficient variant of Jurkat cells, JK-,B-(J.RT3-T3.5, American Type Culture Collection). The expression level of a-PI was comparable to that of 3-PI after the initial drug selection, but continued culture for less than a month yielded a population of cells with little surface expression of a-PI, whereas (3-PI expression was stable (data not shown). The inability to obtain cell lines with stable high-level expression of the PI-anchored human TCR a-chain has been reported by other laboratories as well (24) .
Expression and Purification of a Three-Domain scTCR. To overcome the limitations set by the unstable expression ofthe human TCR a chain, various sc designs were examined. Initially, a design similar to that of sc antibodies (Fv) was chosen (12) . A 15-residue flexible linker was used to link the C terminus of the Vd-Ja domain to the N terminus of the (3 chain. The GPI domain was then ligated to the C terminus of the Vg-Jp domain. The construct (AB-PI-1, Fig. 1 ) was transfected into several cell lines, including JK-/-, COS-7, CHO-Kl, and BW-. Although the expression of the gene was confirmed by the detection of the correct RNA transcripts (Fig. 3B) , no surface expression was detected, as evidenced by negative Cl antibody staining (Fig. 3A) . Immunoprecipitation after metabolic labeling failed to recover any Clreactive sc molecules from these transfectants (data not shown). The inability to identify any Cl-reactive protein could have been due to the design of this molecule, such as insufficient linker length between the extracellular domain and the GPI domain. To improve the accessibility of the sc construct, another two-domain scTCR was designed in which an extra 30-amino acid portion of the N terminus of the CO domain was added as a hinge region. The transfectants ofthis construct (AB-PI-2, Fig. 1 (23) . This three-domain scTCR was constructed by extending the TCR (3-chain sequences to the residue right before the last cysteine (the sixth cysteine), which was then fused to the GPI domain. The last cysteine was deleted to prevent dimerization between C9 domains. This construct (ABC-PI, Fig. 1 ) was transfected into BW-cells and surface expression was confirmed by staining with both 83F1 and Cl (Fig. 3C, shaded curves) . Both antibodies stained the cells with comparable efficiency, suggesting that most of the molecules were expressed in the correct conformation. Moreover, the molecule could be efficiently cleaved from the cell surface with PI-PLC (Fig. 3C, open curves) .
Soluble three-domain scTCR was purified from transfectants after PI-PLC cleavage followed by affinity chromatography using the ,BF1 antibody. The purified three-domain scTCR appeared as multiple bands at 50-70 kDa after SDS/ PAGE (Fig. 3D) . The heterogeneity of scTCR is probably the result of variable glycosylation; its polypeptide size calculated from amino acid composition is 40 kDa. The structural integrity of the three-domain scTCR was verified by a twoantibody ELISA (Fig. 3E) . The molecules were first captured by the ,BF1 antibody immobilized to the plate and then assessed for reactivity with the Cl antibody. When compared with the three-domain scTCR produced in a bacterial expression system (unpublished work), the scTCR from the eukaryotic system gave 10-20 times higher Cl reactivity. The purified three-domain scTCR was stable and could be stored in PBS at 4°C for months without significant loss of Cl reactivity. Functional Characterization of a Chimeric Three-Domain scTCR. To directly assess the functional integrity of the three-domain scTCR, a self-signaling scTCR was produced by replacing the GPI domain with the transmembrane and cytoplasmic domains of the CD3 {chain. These regions have been shown to be sufficient for signal transduction when its Proc. Natl. Acad. Sci. USA 91 (1994) 12657 extracellular fusion partner is crosslinked by an antibody or by the proper ligand (8, 26, 27) . To enable the recovery of three-domain scTCR as a soluble form, a linker containing a thrombin cleavage site was inserted into the junction of three-domain scTCR and the ; domain. The construct (ABC-i) was transfected into BW-cells (28) and the rat basophilic leukemia cell line RBL-2H3 (RBL) (8) , and the populations displaying high-level expression of three-domain scTCR were isolated by three rounds of cytofluorometric sorting using the antibody 8iFI. The ABC--transfected cells were first stimulated with various antibodies to confirm the self-signaling nature ofthis recombinant molecule. The signal transduced upon the activation of the three-domain scTCR was measured as IL-2 production in BW-transfectants, whereas serotonin release was measured in RBL transfectants. Both transfectants showed a strong response following ,8F1 and Cl stimulation but not to purified mouse immunoglobulin or anti-CD8 antibody used as controls (Fig. 4 A and  B) . The structural integrity of the scTCR was further examined with the superantigen SEB, which binds to both Vp17 concentratIon Ot anticocy (gg/mij and MHC class II molecules, resulting in TCR crosslinking and T-cell activation regardless of the peptide bound to the MHC molecule (20, 29) . ABC-; transfectants displayed a concentration-dependent response toward SEB (Fig. 4C) when the superantigen was presented by transformed B-cell lines with high-level expression of DR1 (DRA, DRB1*0101; cell line LG2) or DR2 (DRA, DRB1*1602; cell line 9016). Thus, the lateral face of the TCR V. region to which SEB is thought to bind (30) 
